IDBS and Alchemi Link AI Agents to Regulated Biopharma Data

The collaboration targets the complex Chemistry, Manufacturing, and Controls (CMC) reporting process. By connecting Alchemi’s purpose-built AI agents to the structured, contextualized data foundation within IDBS Polar, the partnership aims to bridge the gap between AI speed and the rigorous demands of regulated environments. According to Alchemi, teams utilizing these agents have reported document production speeds up to 70% faster than traditional methods.

Unlike general-purpose AI tools that often compromise compliance by extracting data from validated systems, this integration keeps information traceable throughout the drug development lifecycle. The workflow routes AI-generated drafts to scientists for review and final sign-off, ensuring every action—human or machine—is recorded in a permanent audit trail. Anuj Chadha, Co-Founder of Alchemi, noted that these agents can draft submission-ready documents in minutes, moving beyond the capabilities of standard demonstration tools to provide actual, compliant regulatory output.